Annual report pursuant to Section 13 and 15(d)

Long-Term Debt and Other Financings (Tables)

v3.20.1
Long-Term Debt and Other Financings (Tables)
12 Months Ended
Dec. 31, 2019
Long-Term Debt and Other Financings  
Aggregate Future Principal, Final Payment Fees and Discounts of Long-Term Debt

Aggregate future principal, final payment fees and discounts of the Company’s long-term debt as of December 31, 2019, are as follows (in thousands):

 

 

 

 

 

Year ending December 31, 2020

 

$

6,030

Year ending December 31, 2021

 

 

8,551

Year ending December 31, 2022

 

 

21,801

Thereafter

 

 

 —

Total payments

 

 

36,382

Less: interest, final payment fees, discount and issuance costs

 

 

(4,105)

Total payments, net of interest, final payment fees, discount and issuance costs

 

 

32,277

Less: current portion of long-term debt

 

 

(5,184)

Long-term debt

 

$

27,093

 

Interest Expense and Amortization of Debt Issuance Costs and Discounts

Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2019 and 2018, relates to the following debt instruments (in thousands):

 

 

 

 

 

 

 

 

 

 

Year Ended December 31, 

 

    

2019

    

2018

SVB loan

 

$

1,207

 

$

258

Novartis note

 

 

706

 

 

627

Other

 

 

 6

 

 

37

Total interest expense

 

$

1,919

 

$

922